Celon PharmaWAR:CLN -2.30%57 EBITDA Margin % is 302.08% as of Mar. 2026, which is 1282% above its 10-year median of 21.86. GuruFocus rates WAR:CLN with a GF Score™ of 57/100 and a GF Value™ of zł22.51 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Celon Pharma ranks better than 98.53% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Celon Pharma's EBITDA for the
three
months ended in Mar. 2026 was zł172.0 Mil. Celon Pharma's Revenue for the
three
months ended in Mar. 2026 was zł56.9 Mil. Therefore, Celon Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 302.08%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Celon Pharma EBITDA Margin % Related Terms
Celon Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Celon Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:CLN vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Celon Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celon Pharma (WAR:CLN) has a EBITDA Margin % of 302.08% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Celon Pharma and its competitors. This is 1282% above median its historical median of 21.86. According to the industry distribution chart, Celon Pharma ranks #14 out of 955 companies in the Drug Manufacturers industry, placing it in the top 1.5%.
Is Celon Pharma's EBITDA Margin % too high?
Celon Pharma's current EBITDA Margin % of 302.08% is 1282% above median its 10-year median of 21.86. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Celon Pharma's value of 302.08% is 2338.1% above this industry median. Based on the distribution chart, Celon Pharma ranks #14 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Celon Pharma has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #14 out of 955 companies for EBITDA Margin %. This places Celon Pharma in the top 2% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Celon Pharma's value of 302.08% is 2338.1% above this benchmark. While the company's 10-year median is 21.86 vs. the industry median of 12.39, Celon Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celon Pharma's current EBITDA Margin % of 302.08% is 2338.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current EBITDA Margin % is 302.08%, which is 1282% above median its own 10-year median of 21.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł22.51, compared to a current price of zł19.52 — trading 13.3% below its estimated fair value. The current EBITDA Margin % is 302.08%, which is 1282% above median its 10-year median of 21.86 and 2338.1% above the Drug Manufacturers industry median of 12.39. Celon Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current EBITDA Margin % is 302.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celon Pharma (WAR:CLN) Overvalued in 2026?
Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued.
The current stock price of zł19.52 is trading 13.3% below its estimated GF Value™ of zł22.51.
GuruFocus considers Celon Pharma to be Modestly Undervalued.
Key valuation signals for WAR:CLN:
EBITDA Margin %: 302.08% (1282% above median its 10-year median of 21.86)
GF Value™: zł22.51 vs. price of zł19.52 (13.3% below fair value)
Industry Position: 2338.1% above the Drug Manufacturers median (#14 of 955)
No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
57GF Score
Get the complete analysis for WAR:CLN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CLN has been successfully added to your 
